Aviptadil for ARDS: Synthetic VIP in Acute Lung Injury

The clinical problem

Acute respiratory distress syndrome (ARDS) is a severe, life-threatening form of lung injury in which the air sacs fill with fluid and the lungs stiffen, causing dangerously low blood oxygen. It can be triggered by pneumonia, sepsis, trauma, or viral infection — and it became tragically familiar during the COVID-19 pandemic. The cornerstone of care is supportive: careful mechanical ventilation, oxygen, and treatment of the underlying cause. There is no simple drug that cures ARDS, which is why new pharmacologic approaches attract intense interest. This use case is educational; ARDS is managed in intensive care.

The rationale for VIP

The lung is unusually rich in vasoactive intestinal peptide (VIP), a signaling molecule that relaxes airway and vascular smooth muscle and has anti-inflammatory properties. VIP is also concentrated in the cells that line the air sacs. The therapeutic hypothesis is that supplying extra VIP might protect those cells, reduce inflammation, and support gas exchange in an injured lung.

Aviptadil is a synthetic form of VIP developed to test this idea (studied under names including Zyesami and RLF-100). It was investigated in acute respiratory distress syndrome, with particular attention to critically ill patients with COVID-19 who had respiratory failure.

What the evidence showed

Aviptadil was studied in randomized trials in severe respiratory failure, including COVID-19-related ARDS. The results have been mixed and not definitive. Some analyses suggested possible signals of benefit in particular subgroups, while the overall picture did not establish a clear, reliable advantage sufficient for approval.

As a result, aviptadil is not an approved treatment for ARDS in the United States or generally; it remains investigational (research-only) for this indication. We avoid quoting specific trial percentages here because the honest summary is qualitative: the evidence did not convincingly demonstrate that aviptadil improves the outcomes that matter most in ARDS. This is a common and important outcome in critical-care research, where many biologically plausible therapies fail to show benefit in rigorous trials.

A different, established use

It is worth distinguishing the investigational ARDS work from a separate, long-standing use of VIP. Combined with phentolamine in a formulation called Invicorp, VIP is approved in some European countries, including the UK (prescription-only), for erectile dysfunction by intracavernosal injection. That approval rests on VIP's vasodilatory action and is entirely separate from the unproven ARDS indication. The contrast underscores that a molecule can be an approved drug for one narrow purpose while remaining experimental for another.

Where it fits

For ARDS today, aviptadil is best regarded as a research agent, not part of standard care. Management continues to rest on lung-protective ventilation, treatment of the underlying trigger, and organ support. Aviptadil's story is a reminder that a sound mechanistic rationale — a lung-protective peptide for a lung disease — is a starting point for investigation, not evidence of efficacy on its own.

For the broader biology behind it, including the rare VIP-secreting tumor (VIPoma) and how somatostatin analogs like octreotide are used to counter VIP excess, see vasoactive intestinal peptide.

The bottom line

Aviptadil is synthetic VIP investigated for ARDS, including COVID-19, on the logic that a lung-protective, anti-inflammatory peptide might help injured lungs. The trial evidence is mixed, and it is not an approved ARDS treatment. It should be viewed as investigational, distinct from VIP's approved use in erectile dysfunction in parts of Europe.

This use case is educational and not medical advice. Aviptadil is not approved for ARDS; ARDS is managed by intensive-care clinicians.